Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04685135 · FLOW

Participant flow

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation · Source last updated 2026-08-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).
    id
    FG000
    title
    Adagrasib
  2. description
    Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\^2 over 1 hour or according to institutional practices.
    id
    FG001
    title
    Docetaxel
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        126
      2. group Id
        FG001
        num Subjects
        53
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        12
      2. group Id
        FG001
        num Subjects
        16
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        301
      2. group Id
        FG001
        num Subjects
        152
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        298
      2. group Id
        FG001
        num Subjects
        140
      comment
      Participants who received at least one dose of study treatment.
      type
      Safety Population
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. comment
        Patients who crossed over from Docetaxel to Adagrasib are included in the Docetaxel arm only.
        group Id
        FG001
        num Subjects
        44
      comment
      Eligible participants receiving Docetaxel based on physician switched to treatment with Adagrasib
      type
      Cross Over
    4. achievements
      1. group Id
        FG000
        num Subjects
        163
      2. group Id
        FG001
        num Subjects
        83
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        138
      2. group Id
        FG001
        num Subjects
        69
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).
    id
    FG000
    title
    Adagrasib
  2. description
    Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\^2 over 1 hour or according to institutional practices.
    id
    FG001
    title
    Docetaxel
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        126
      2. group Id
        FG001
        num Subjects
        53
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        12
      2. group Id
        FG001
        num Subjects
        16
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        301
      2. group Id
        FG001
        num Subjects
        152
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        298
      2. group Id
        FG001
        num Subjects
        140
      comment
      Participants who received at least one dose of study treatment.
      type
      Safety Population
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. comment
        Patients who crossed over from Docetaxel to Adagrasib are included in the Docetaxel arm only.
        group Id
        FG001
        num Subjects
        44
      comment
      Eligible participants receiving Docetaxel based on physician switched to treatment with Adagrasib
      type
      Cross Over
    4. achievements
      1. group Id
        FG000
        num Subjects
        163
      2. group Id
        FG001
        num Subjects
        83
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        138
      2. group Id
        FG001
        num Subjects
        69
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice